I Want You Back: Putting The Patient Into Policy
This article was originally published in Scrip
Time was when the patient barely got a look in where drug development was concerned. Pharma firms would identify a new substance with therapeutic potential in a disease like breast cancer or hypertension, develop a drug and get it approved. Patients were at the receiving end and had little or no say in how the drug was conceived, developed and evaluated. The regulators themselves had little idea of the impact their decisions and policies had on patients' everyday lives.
You may also be interested in...
New guidance from the UK covers the recognition of EU approvals, accelerated assessment, rolling reviews, and much else besides.
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.